[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-stem-cell-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-stem-cell-transplant":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,55,82,102,125,150,179,226],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054296","prevalence-and-development-of-liver-dysfunction-in-hematopoietic-stem-cell-transplant-100054296",false,"NCT05722210","Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant","Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant: A Prospective Natural History Study","* INCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be included in this study:\n\n* Male and female adults \\>=18 years of age and children 3-17 years of age\n* Undergoing evaluation for hematopoietic stem cell transplant at the NIH Clinical Center\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this\n\nstudy:\n\n* Pregnancy or lactation\n* Unable to comply with study procedures\n* Inability to provide written informed consent","ALL","3 Years","90 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","Background:\n\nHematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But many people who have HSCT go on to develop liver dysfunction. Researchers want to know more about how and why this happens. In this natural history study, they will try to learn what factors lead to liver dysfunction; how underlying liver disease may affect the results of HSCT; and how HSCT may contribute to liver dysfunction.\n\nObjective:\n\nTo understand the links between HSCT and liver dysfunction.\n\nEligibility:\n\nAdults aged 18 years or older and children 3 to 17 years who are being evaluated for HSCT.\n\nDesign:\n\nThis study involves 11 visits in 4 years. Most visits will be in the first year.\n\nBefore and after their HSCT, participants will undergo these tests:\n\nPhysical exam, including blood tests and a test of heart function. Participants will provide stool samples.\n\nLiver biopsies. Samples of liver tissue will be removed. This may be done either by inserting a needle through the right side of the chest, or with a thin tube threaded to the liver from a vein in the neck. Adult participants will undergo this procedure 2 times: once before the HSCT and once about a year later.\n\nImaging scans. Participants will lie on a bed that moves into either a cylinder or a donut-shaped machine.\n\nUltrasound. Participants will lie still. A probe that uses sound waves will be slid over their skin to get pictures of the liver.\n\nFibroscan exam. This is like an ultrasound that uses a special probe to measure the toughness of the liver.\n\n...",[25],"Hematopoietic Stem Cell Transplant",[27,28,29],"Liver Disease","Liver Dysfunction","Natural History","NOT_YET_RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":21},"2026-07-16",{"date":38,"type":21},"2031-06-30",{"name":40,"class":41},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":44,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":45,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":46,"keywords":47,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":54,"locationsCount":42},"100494748",{"count":20,"type":21},[25],[27,28,29],"2026-07-01",{"date":50,"type":34},"2026-07-02",{"date":52,"type":21},"2026-07-07",{"date":38,"type":21},{"name":40,"class":41},{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":42},"100560328","coping-skills-training-for-symptom-management-and-daily-steps-step-up-100560328","NCT06575712","Coping Skills Training for Symptom Management and Daily Steps (Step Up)","Inclusion Criteria:\n\n* receipt of an autologous (auto) HCT or CAR-T cell therapy due to a hematologic malignancy, such as a diagnosis of leukemia, lymphoma, multiple myeloma\n* age \\>18\n* self-reported fatigue, pain, and psychological distress (confirmed at recruitment) - minimum two of three symptoms reported at \\>3 on 0-10 scale\n* life expectancy \\> 12 months\n\nExclusion Criteria:\n\n* cognitive impairment (e.g., dementia) recorded in the chart or suspected by provider\n* metastases to the brain\n* presence of a severe psychiatric condition (e.g., psychotic disorder) that would contraindicate safe participation as indicated by the medical chart, treating oncologist, or interactions with the medical\u002Fstudy staff\n* inability to converse in English","18 Years","99 Years",{"count":64,"type":21},177,"INTERVENTIONAL",[67],"NA","The aim of this study is to test the efficacy of a hybrid in-person and mHealth coping skills training and activity coaching intervention (Step Up), to enable HCT patients to effectively cope with symptoms (pain, fatigue, and stress) to improve their ability to engage in physical activity that can improve physical disability.",[25,70],"CAR-T Cell Therapy","RECRUITING","2026-06-24",{"date":74,"type":34},"2026-06-25",{"date":76,"type":34},"2025-04-21",{"date":78,"type":21},"2029-07-15",{"name":80,"class":81},"Duke University","OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":65,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100641834","meaning-centered-psychotherapy-for-addressing-existential-distress-of-patientcaregiver-dyads-following-hematopoietic-stem-cell-transplantation-feasibility-and-acceptability-100641834","NCT07595146","Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient\u002FCaregiver Dyads Following Hematopoietic Stem Cell Transplantation: Feasibility and Acceptability","Inclusion criteria:\n\n* Eligible patients and their caregivers must be adults (≥18 years)\n* Patient must have undergone HSCT for a malignant blood cancer condition\n* Caregiver must be the main support person (e.g., signed caregiving contract) for the HSCT patient\n* Both the patient and their caregiver must be willing to participate in the study (dyads only)\n* Be able to read, write, and speak in English\n* Have access to a smartphone, computer, or tablet necessary for study participation and assessments. If a patient\u002Fcaregiver dyad is interested in participating but does not have such a device, we will provide a Tracfone with smartphone capabilities for each member of the dyad\n\nExclusion criteria:\n\n* Patients undergoing HSCT for nonmalignant conditions\n* Patients and caregivers with severe cognitive or psychiatric impairment that may affect informed consent\u002Fparticipation\n* Prisoners, pregnant women, and institutionalized persons\n* Patients with severe cognitive or psychiatric impairment that would affect informed consent or participation",{"count":89,"type":21},100,[67],"The purpose of this study is to learn whether Meaning-Centered Psychotherapy (MCP-Dyad) is practical, acceptable, and helpful to survivors and caregivers during recovery after stem cell transplant. MCP-Dyad is a meaning-focused support program. It is designed to help people stay connected to meaning, cope with difficult experiences, and communicate as a pair during recovery.",[25],"2026-06-17",{"date":95,"type":34},"2026-06-22",{"date":97,"type":21},"2026-08-01",{"date":99,"type":21},"2028-04-30",{"name":101,"class":81},"Mayo Clinic",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":65,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":42},"100511874","prehabilitation-program-to-improve-cardiac-reserve-in-high-risk-patients-undergoing-hematopoietic-stem-cell-transplantation-100511874","NCT05945121","Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation","Cardio-Oncology Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Adult 18 years or older\n* Referred for HSCT evaluation\n* Presence of least one CV risk factor at enrollment (hypertension, hyperlipidemia, atrial fibrillation, obesity, heart failure, history of coronary artery disease, diabetes)\n* Able to ambulate unassisted\n* Ability to understand and the willingness to sign a written informed consent\n* Ability to use Polar Flow heart rate application\n\nExclusion Criteria:\n\n* Severe anemia (hemoglobin \\\u003C7 gm\u002Fdl)\n* Untreated high-risk coronary artery disease (left main, triple vessel disease)\n* Severe aortic stenosis\n* Recent fracture as assessed via self-report\n* Gross balance deficits\n* Severe pain with basic movement\n* Unable to ambulate unassisted or exercise\n* NYHA class IV heart failure\n* Adults unable to give consent, pregnant women, and prisoners are excluded from this study.",{"count":110,"type":21},10,[67],"To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.",[25],[115],"Cardiovascular disease","2026-05-01",{"date":118,"type":34},"2026-05-04",{"date":120,"type":34},"2023-08-25",{"date":122,"type":21},"2027-08",{"name":124,"class":81},"University of Michigan Rogel Cancer Center",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":65,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100541305","positive-psychology-intervention-for-hematopoietic-stem-cell-transplantation-survivors-100541305","NCT06328127","Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors","PATH-4","Inclusion Criteria:\n\n* Adult patients (aged 18 years and older) undergoing allogeneic HSCT and are approaching 100-days post-HSCT\n* Ability to speak, read, and respond to questions in English or Spanish to complete study procedures\n* Access to a basic telephone\n\nExclusion Criteria:\n\n* Patients who underwent allogeneic HSCT for benign hematologic conditions\n* Patients with severe psychiatric or cognitive conditions, such as dementia, determined by their transplant oncologist to make them unable to provide informed consent or comply with study procedures",{"count":133,"type":21},400,[67],"This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared to usual care.",[25],[138,139],"stem cell transplant","positive psychology intervention","2025-11-11",{"date":142,"type":34},"2025-11-13",{"date":144,"type":34},"2024-12-17",{"date":146,"type":21},"2030-05-31",{"name":148,"class":81},"Brigham and Women's Hospital",3,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":65,"phases":160,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":42},"100284461","early-phase-1-t-cell-therapy-of-opportunistic-cytomegalovirus-infection-100284461","NCT02982902","T Cell Therapy of Opportunistic Cytomegalovirus Infection","Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell Transplant","Inclusion Criteria:\n\n* Patients must have received allogeneic hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registration\n* Patients must have documented opportunistic CMV infection, or reactivation; the criteria include (both of the following criteria must be met)\n\n  * Patients may have asymptomatic viremia (\\>1000 copies\u002Fml) OR presence of symptoms secondary to CMV infection, AND\n  * Patients must have ONE OF THE NEXT FOUR CRITERIA:\n\n    * Absence of an improvement of viral load after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir or foscarnet (decrease by at least 1 log, i.e. 10-fold) or\n    * New, persistent and\u002For worsening CMV-related symptoms, signs and\u002For markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet, or\n    * Have contraindications or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir or foscarnet.\n    * Second recurrence of CMV viremia, CMV-related symptoms, signs and\u002For markers of end organ compromise.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3\n* Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry, for the duration of study participation and for 3 months after completing treatment.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document, or assent document.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women are excluded from this study.\n* Patients with opportunistic viral infections other than CMV.\n* Patients with active, grade 2-4, acute graft vs. host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (\\>0.5 mg\u002Fkg\u002Fday prednisone or its equivalent) as treatment\n* Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells.\n* Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion.\n\nDonor eligibility\n\n* Related donor of T cells must be at least partially HLA compatible, matching with recipient in at least 3\u002F6 HLA loci (HLA-A, HLA-B, and HLA-DRB1 loci will be considered for this).\n* Must have evidence of a serologic response (i.e. be seropositive) against CMV.\n* Age ≥ 18 years\n* Must meet the criteria for donor selection defined in the Standard Operating Procedures of University Hospitals Seidman Cancer Center Stem Cell Transplant Program\n* Must be capable of undergoing a single standard 2 blood volume leukapheresis or donation of one unit of whole blood","3 Months",{"count":159,"type":21},20,[161],"EARLY_PHASE1","The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV.\n\nAdoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).",[164,25,165],"Cytomegalovirus Infections","Opportunistic Infections",[167,168,169],"Immunotherapy","T-Cell Therapy","Lymphoproliferative Disorder","2025-10-20",{"date":172,"type":34},"2025-10-22",{"date":174,"type":34},"2020-05-27",{"date":176,"type":21},"2028-08",{"name":178,"class":81},"Mari Dallas",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":65,"phases":188,"briefSummary":190,"conditions":191,"keywords":202,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":225},"100551613","phase-1-prevention-of-gvhd-in-participants-with-hematological-malignancies-undergoing-hematopoietic-stem-cell-transplant-hsct-100551613","NCT06462365","Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)","Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)","Inclusion Criteria:\n\n1. Subjects with one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (B- or T-ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML)\n2. Males and Females Age ≥ 18 years.\n3. Weight of ≥ 35 Kg.\n4. Karnofsky performance status ≥ 70 %.\n5. Available mismatched related (haploidentical) or unrelated donors for peripheral blood stem cell (PBSC) donation.\n6. Subjects must otherwise fulfill institutional criteria for eligibility to undergo allogeneic stem cell transplantation.\n7. Absence of uncontrolled bacterial, viral or fungal infection at time of enrollment.\n8. Have adequate organ function.\n9. Subjects \\> 65-year-old receiving MAC conditioning will only be eligible if they have a HSCT-comorbidity index score \\\u003C 5.\n10. Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.\n\nExclusion Criteria:\n\n1. Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT.\n2. Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction.\n3. HIV positive.\n4. Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.\n5. Positive hepatitis-C antibody with positive Recombinant Immunoblot Assay (RIBA) or PCR unless the subject has received curative anti-viral treatment and confirmed negative viral load by PCR.\n6. Received another investigational agent for treatment of disease understudy within 28 days (or 5 half-lives, whichever is shorter) of conditioning and\u002For have not recovered from treatment related toxicities.\n7. Subjects with a previous history of Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS) who are not good candidates for treatment with sirolimus.\n8. Subjects that are pregnant, breast feeding or aim to become pregnant during the study period. (Subjects must agree to use a highly effective method of contraception).\n9. Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results.",{"count":187,"type":21},36,[189],"PHASE1","The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.",[192,193,194,195,25,196,197,198,199,200,201],"Hematologic Malignancy","GvHD","GVHD,Acute","GVHD, Chronic","Acute Lymphoblastic Leukemia, Adult B-Cell","Acute Lymphoblastic Leukemia, Adult T-Cell","Acute Myeloid Leukemia in Remission","Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia, in Remission","Cancer Remission",[203,204,205,206,207,208,209,210,211,212,213,214],"AML","CMML","Stem Cell Transplant","B-ALL","T-ALL","Acute GvHD","Graft versus Host Disease","Chronic GvHD","MDS","Cellular Therapy","Autoimmune","T regulatory cells","2025-04-10",{"date":217,"type":34},"2025-04-15",{"date":219,"type":34},"2024-04-08",{"date":221,"type":21},"2027-04-15",{"name":223,"class":224},"Tr1X, Inc.","INDUSTRY",5,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":232,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":65,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":4},"100577002","a-study-of-the-effect-of-laughter-therapy-on-the-mental-health-and-quality-of-survival-of-hematopoietic-stem-cell-transplant-patients-100577002","NCT06792630","A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem Cell Transplant Patients","Inclusion Criteria:\n\nPatients with a pathologically confirmed diagnosis of hematologic malignancy; Patients undergoing their first hematopoietic stem cell transplant; Age ≥ 16 years; Those who have some reading and writing ability; Those who can cooperate in completing the questionnaires and assessments; Informed consent and voluntary participation in the study.\n\nExclusion Criteria:\n\nThose with severe mental illness or personality disorders; Those who cannot operate a smartphone independently; Those with severe visual and hearing impairments; Those who are critically ill and cannot receive the intervention.","16 Years",{"count":234,"type":21},98,[67],"主要研究目的：\n\n1)探讨笑疗法在造血干细胞移植患者移植心理健康及生存质量中的效果。 次要研究目的：\n\n1. 了解造血干细胞移植患者移植后3个月、6个月、1年内的心理健康变化和生存质量水平；\n2. 探讨笑疗法在造血干细胞移植患者预后等结局指标中的应用效果。",[192,25],"2025-01-21",{"date":240,"type":34},"2025-01-24",{"date":242,"type":21},"2025-01-31",{"date":244,"type":21},"2026-11-30",{"name":246,"class":81},"Institute of Hematology & Blood Diseases Hospital, China"]